Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma, Inc. (LUMO)
Company Research
Source: GlobeNewswire
AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand. Abstract Presentation: Thursday, October 3rd – Oral Session: Growth & Puberty – 2:30PM Local Time Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial (Paul Hofma
Show less
Read more
Impact Snapshot
Event Time:
LUMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUMO alerts
High impacting Lumos Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
LUMO
News
- Lumos Pharma, Inc. (NASDAQ: LUMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.MarketBeat
- Lumos Pharma, Inc. (NASDAQ: LUMO) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.MarketBeat
- Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024GlobeNewswire
- Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswire
- Lumos Pharma, Inc. (NASDAQ: LUMO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $16.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
LUMO
Earnings
- 8/1/24 - Beat
LUMO
Sec Filings
- 8/6/24 - Form 4
- 8/5/24 - Form 4
- 8/5/24 - Form 4
- LUMO's page on the SEC website